Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
Ludwig-Maximilians-Universität München · CureVac (Germany) · +2 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
534
total citations
- FWCI
- 15.07
- Percentile
- 100%
- References
- 27
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Medicine
- Immunogenicity
- Tolerability
- Rabies
- Vaccination
- Clinical endpoint
- Clinical trial
- Syringe
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.